Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

The biotech, which has raised more than $140 million over several investment rounds in the last few years from the likes of ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...

Transcend also saw significant improvements on secondary endpoints that assessed the rate of response, remission and loss of ...

Cologuard is getting an upgrade after 10 years on the market, as Exact Sciences starts to roll out the new version of its ...